Scalable continuous-flow electroporation platform enabling T cell transfection for cellular therapy manufacturing

Jacob A. VanderBurgh, Thomas N. Corso, Stephen L. Levy, Harold G. Craighead

Research output: Contribution to journalArticlepeer-review

6 Scopus citations


Viral vectors represent a bottleneck in the manufacturing of cellular therapies. Electroporation has emerged as an approach for non-viral transfection of primary cells, but standard cuvette-based approaches suffer from low throughput, difficult optimization, and incompatibility with large-scale cell manufacturing. Here, we present a novel electroporation platform capable of rapid and reproducible electroporation that can efficiently transfect small volumes of cells for research and process optimization and scale to volumes required for applications in cellular therapy. We demonstrate delivery of plasmid DNA and mRNA to primary human T cells with high efficiency and viability, such as > 95% transfection efficiency for mRNA delivery with < 2% loss of cell viability compared to control cells. We present methods for scaling delivery that achieve an experimental throughput of 256 million cells/min. Finally, we demonstrate a therapeutically relevant modification of primary T cells using CRISPR/Cas9 to knockdown T cell receptor (TCR) expression. This study displays the capabilities of our system to address unmet needs for efficient, non-viral engineering of T cells for cell manufacturing.

Original languageEnglish (US)
Article number6857
Pages (from-to)6857
JournalScientific Reports
Issue number1
StatePublished - Apr 26 2023


  • Humans
  • T-Lymphocytes
  • Transfection
  • Electroporation/methods
  • Genetic Vectors
  • RNA, Messenger

ASJC Scopus subject areas

  • General


Dive into the research topics of 'Scalable continuous-flow electroporation platform enabling T cell transfection for cellular therapy manufacturing'. Together they form a unique fingerprint.

Cite this